Synergistic targeting of the regulatory and catalytic · 2017. 12. 15. · evidence that phosphodiesterase 4 (PDE4) inhibition also suppresses BCR signals. We show that combination
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Synergistic targeting of the regulatory and catalytic
subunits of PI3Kδ in mature B cell malignancies
Jeffrey D. Cooney1*, An-Ping Lin1*, Daifeng Jiang1, Long Wang1, Avvaru N.
Suhasini1, Jamie Myers1, ZhiJun Qiu1, Albert Wölfler2, Heinz Sill2
and Ricardo C.T. Aguiar1,3,4
1. Division of Hematology and Medical Oncology, Department of Medicine, University of Texas
Health Science Center at San Antonio, San Antonio, TX 78229, USA;
2. Division of Hematology, Medical University of Graz, Graz A-8036, Austria;
3. Greehey Children's Cancer Research Institute, University of Texas Health Sciences Center at
San Antonio, San Antonio, TX 78229;
4. South Texas Veterans Health Care System, Audie Murphy VA Hospital, San Antonio, San
Antonio, TX 78229.
* Equal contribution
Running Title: basis for the synergism between PDE4 and PI3Kδ inhibitors
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
References: 1. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell
malignancies. Nature reviews Immunology 2013;13(8):578-91 doi 10.1038/nri3487. 2. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid
malignancies. Nature reviews Drug discovery 2013;12(3):229-43 doi 10.1038/nrd3937. 3. Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and
strategies for management. Blood 2015;126(4):471-7 doi 10.1182/blood-2015-03-585075.
4. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016;374(4):323-32 doi 10.1056/NEJMoa1509981.
5. Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood 2016;128(3):331-6 doi 10.1182/blood-2016-02-702761.
6. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 2016;128(2):195-203 doi 10.1182/blood-2016-03-707133.
7. Barr PM, Saylors GB, Spurgeon SE, Cheson BD, Greenwald DR, O'Brien SM, et al. Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 2016;127(20):2411-5 doi 10.1182/blood-2015-12-683516.
8. Cheson BD. Speed bumps on the road to a chemotherapy-free world for lymphoma patients. Blood 2016;128(3):325-30 doi 10.1182/blood-2016-04-709477.
9. Cooney JD, Aguiar RC. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. Blood 2016;128(25):2886-90 doi 10.1182/blood-2016-09-737676.
10. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005;105(1):308-16 doi 10.1182/blood-2004-01-0240.
11. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8(1):68-74 doi 10.1038/nm0102-68.
12. Kim SW, Rai D, McKeller MR, Aguiar RC. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood 2009;113(24):6153-60 doi 10.1182/blood-2009-02-206128.
13. Suhasini AN, Wang L, Holder KN, Lin AP, Bhatnagar H, Kim SW, et al. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma. Leukemia 2016;30(3):617-26 doi 10.1038/leu.2015.302.
14. Kim SW, Rai D, Aguiar RC. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(21):6723-32 doi 10.1158/1078-0432.CCR-11-0770.
15. Kelly K, Mejia A, Suhasini AN, Lin AP, Kuhn J, Karnad AB, et al. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 2017;23(5):1186-92 doi 10.1158/1078-0432.CCR-16-1207.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
16. Bouamar H, Abbas S, Lin AP, Wang L, Jiang D, Holder KN, et al. A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. Blood 2013;122(5):726-33 doi 10.1182/blood-2013-04-495804.
17. Lin AP, Abbas S, Kim SW, Ortega M, Bouamar H, Escobedo Y, et al. D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nature communications 2015;6:7768 doi 10.1038/ncomms8768.
18. Elkashef SM, Lin AP, Myers J, Sill H, Jiang D, Dahia PLM, et al. IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. Cancer cell 2017;31(5):619-20 doi 10.1016/j.ccell.2017.04.001.
19. Jiang D, Aguiar RC. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta1/SMAD5 signaling module. Blood 2014;123(1):86-93 doi 10.1182/blood-2013-07-515254.
20. Campbell V TR, Villegas V, Proctor J, McGovern K, Kutok JL, Stern HM. . The potent PI3K-δ,γ inhibitor, IPI-145, exhibits differential activity in diffuse large B-cell lymphoma (DLBCL) cell lines. Blood 2013;122:1832.
21. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003;101(10):4122-30 doi 10.1182/blood-2002-10-3208.
22. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res 2007;13(16):4920-7.
23. Jones JA, Byrd JC. How will B-cell-receptor-targeted therapies change future CLL therapy? Blood 2014;123(10):1455-60 doi 10.1182/blood-2013-09-453092.
24. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood 2015;126(25):2686-94 doi 10.1182/blood-2015-03-630947.
25. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. Journal of immunology (Baltimore, Md : 1950) 2015;194(1):101-12 doi 10.4049/jimmunol.1401854.
26. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116(12):2078-88 doi 10.1182/blood-2010-02-271171.
27. Beitz LO, Fruman DA, Kurosaki T, Cantley LC, Scharenberg AM. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999;274(46):32662-6.
28. Moon KD, Post CB, Durden DL, Zhou Q, De P, Harrison ML, et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 2005;280(2):1543-51 doi 10.1074/jbc.M407805200.
29. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nature reviews Immunology 2010;10(6):387-402 doi 10.1038/nri2765.
30. Mellor P, Furber LA, Nyarko JN, Anderson DH. Multiple roles for the p85alpha isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochem J 2012;441(1):23-37 doi 10.1042/BJ20111164.
31. Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res 2015;21(7):1537-42 doi 10.1158/1078-0432.CCR-14-2034.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
32. Baba Y, Hashimoto S, Matsushita M, Watanabe D, Kishimoto T, Kurosaki T, et al. BLNK mediates Syk-dependent Btk activation. Proc Natl Acad Sci U S A 2001;98(5):2582-6.
33. Saito K, Scharenberg AM, Kinet JP. Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem 2001;276(19):16201-6 doi 10.1074/jbc.M100873200.
34. Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Current opinion in cell biology 2017;45:62-71 doi 10.1016/j.ceb.2017.02.007.
35. Fruman DA, Cantley LC. Idelalisib--a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med 2014;370(11):1061-2 doi 10.1056/NEJMe1400055.
36. Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, et al. Simultaneous Inhibition of PI3Kdelta and PI3Kalpha Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-kappaB and AKT. Cancer Cell 2017;31(1):64-78 doi 10.1016/j.ccell.2016.12.003.
37. Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J Exp Med 2012;209(3):463-70 doi 10.1084/jem.20112533.
38. de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Human molecular genetics 1994;3(1):161-6.
39. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004;24(3):1007-21.
40. Zhang J, Walk SF, Ravichandran KS, Garrison JC. Regulation of the Src homology 2 domain-containing inositol 5'-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase. J Biol Chem 2009;284(30):20070-8 doi 10.1074/jbc.M109.016865.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2017/12/15/1078-0432.CCR-17-2218To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 15, 2017; DOI: 10.1158/1078-0432.CCR-17-2218